AIM ImmunoTech Inc.
AIMAMEXHealthcare● Active
$0.52
+$0.00(+0.60%)
Market Cap$1766097
P/E Ratio—
52W High$19.73812
52W Low$0.21
AIM ImmunoTech Inc. (AIM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AIM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.69
Est. -$1.08 · +36.1%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
AIM reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.17 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$1.08 | -$0.69 | +36.1% | $0.00B | $0.00B | +0.0% |
| ▲ Q1 FY2026 | Mar 27, 2026 | -$0.94 | -$0.44 | +53.2% | $0.00B | $0.00B | -79.0% |
| ▼ Q4 FY2025 | Nov 17, 2025 | -$0.97 | -$1.57 | -61.0% | $0.00B | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$8.00 | -$3.68 | +54.0% | $0.00B | $0.00B | -75.0% |
| ▲ Q2 FY2025 | May 15, 2025 | -$8.00 | -$5.00 | +37.5% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$9.00 | -$10.00 | -11.1% | $0.00B | $0.00B | -55.0% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$10.00 | -$6.00 | +40.0% | $0.00B | $0.00B | -65.0% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.69
EPS Est.
-$1.08
EPS Surpr.
+36.1%
Revenue
$0.00B
Q1 FY2026
Mar 27, 2026Beat
EPS Actual
-$0.44
EPS Est.
-$0.94
EPS Surpr.
+53.2%
Revenue
$0.00B
Q4 FY2025
Nov 17, 2025Miss
EPS Actual
-$1.57
EPS Est.
-$0.97
EPS Surpr.
-61.0%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$3.68
EPS Est.
-$8.00
EPS Surpr.
+54.0%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$5.00
EPS Est.
-$8.00
EPS Surpr.
+37.5%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$10.00
EPS Est.
-$9.00
EPS Surpr.
-11.1%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$6.00
EPS Est.
-$10.00
EPS Surpr.
+40.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q3 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q2 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q1 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q4 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +36.1% | $0.26 | $0.25 | -1.94% |
| ▲ Q1 FY2026 | Mar 27, 2026 | +53.2% | $0.69 | $0.70 | +1.23% |
| ▼ Q4 FY2025 | Nov 17, 2025 | -61.0% | $1.33 | $1.44 | +8.27% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +54.0% | $2.51 | $2.42 | -3.59% |
| ▲ Q2 FY2025 | May 15, 2025 | +37.5% | $8.47 | $8.47 | +0.00% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -11.1% | $12.23 | $12.23 | +0.00% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +40.0% | $22.58 | $23.52 | +4.16% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -2400.0% | $25.40 | $25.40 | +0.00% |
Q2 FY2026-1.94%
Report Date
May 15, 2026
EPS Beat/Miss
+36.1%
Price Before
$0.26
Price After
$0.25
Q1 FY2026+1.23%
Report Date
Mar 27, 2026
EPS Beat/Miss
+53.2%
Price Before
$0.69
Price After
$0.70
Q4 FY2025+8.27%
Report Date
Nov 17, 2025
EPS Beat/Miss
-61.0%
Price Before
$1.33
Price After
$1.44
Q3 FY2025-3.59%
Report Date
Aug 14, 2025
EPS Beat/Miss
+54.0%
Price Before
$2.51
Price After
$2.42
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
+37.5%
Price Before
$8.47
Price After
$8.47
Q1 FY2025+0.00%
Report Date
Mar 27, 2025
EPS Beat/Miss
-11.1%
Price Before
$12.23
Price After
$12.23
Q4 FY2024+4.16%
Report Date
Nov 14, 2024
EPS Beat/Miss
+40.0%
Price Before
$22.58
Price After
$23.52
Q3 FY2024+0.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
-2400.0%
Price Before
$25.40
Price After
$25.40
Avg Beat Reaction-0.03%
Avg Miss Reaction+2.76%
Beat Rate5 / 8 quarters
Largest Move+8.27% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AIM ends December
AIM ImmunoTech Inc. (AIM) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.69 — beating the analyst consensus of $-1.08 by +36.1%. AIM has beaten EPS estimates for 2 consecutive quarters. The next AIM earnings date is expected around September 1, 2026.
Each quarter, investors track AIM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AIM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AIM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AIM earnings · 5 questionsAIM ImmunoTech Inc.'s next earnings report is expected around September 1, 2026. AIM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AIM historically reports after market close (AMC).
AIM earnings datewhen is AIM earningsAIM next earnings datewhen does AIM report earningsAIM earnings calendar
▸ Source: FMP · AIM ImmunoTech Inc. SEC filings · US GAAP · AIM ImmunoTech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026